A new technology for targeting proteins inside cells

In the September issue of MedNous Dr Mark Vaeck, CEO of Complix, provides an update on the recent progress achieved by the Company.

Over the past decade our Belgium-based company Complix NV has developed a preclinical portfolio of biologics directed against intracellular targets that we believe represents a novel approach for treating cancer and other important diseases. In our lead programme we are currently selecting a development candidate with a view to bringing our first product into the clinic. In this article we explain how we arrived at this point in the company’s development.

The article was written by Dr Mark Vaeck, co-founder and Chief Executive Officer of Complix NV.



Complix NV
Dr. Mark Vaeck
+32 9 261 69 40